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Abstract
Background: Postoperative delirium may manifest in the immediate post-anaesthesia care period. Such episodes
appear to be predictive of further episodes of inpatient delirium and associated adverse outcomes. Frontal
electroencephalogram (EEG) findings of suppression patterns and low proprietary index values have been
associated with postoperative delirium and poor outcomes. However, the efficacy of titrating anaesthesia to
proprietary index targets for preventing delirium remains contentious. We aim to assess the efficacy of two
strategies which we hypothesise could prevent post-anaesthesia care unit (PACU) delirium by maximising the alpha
oscillation observed in frontal EEG channels during the maintenance and emergence phases of anaesthesia.
Methods: This is a 2 × 2 factorial, double-blind, stratified, randomised control trial of 600 patients. Eligible patients
are those aged 60 years or over who are undergoing non-cardiac, non-intracranial, volatile-based anaesthesia of
expected duration of more than 2 h. Patients will be stratified by pre-operative cognitive status, surgery type and
site. For the maintenance phase of anaesthesia, patients will be randomised (1:1) to an alpha power-maximisation
anaesthesia titration strategy versus standard care avoiding suppression patterns in the EEG. For the emergence
phase of anaesthesia, patients will be randomised (1:1) to early cessation of volatile anaesthesia and emergence
from an intravenous infusion of propofol versus standard emergence from volatile anaesthesia only. The primary
study outcomes are the power of the frontal alpha oscillation during the maintenance and emergence phases of
anaesthesia. Our main clinical outcome of interest is PACU delirium.
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Discussion: This is a largely exploratory study; the extent to which EEG signatures can be modified by titration of
pharmacological agents is not known. The underlying concept is maximisation of anaesthetic efficacy by
individualised drug titration to a clearly defined EEG feature. The interventions are already clinically used strategies
in anaesthetic practice, but have not been formally evaluated. The addition of propofol during the emergence
phase of volatile-based general anaesthesia is known to reduce emergence delirium in children; however, the
efficacy of this strategy in older patients is not known.
Trial registration: Australian and New Zealand Clinical Trial Registry, ID: 12617001354370. Registered on 27/09/2017.
Keywords: General anaesthesia, Anaesthesia emergence, Delirium, EEG monitoring, Elderly
Background and rationale
There is current interest in the use of electroencephalo-
graphic (EEG)-guided administration of anaesthesia to
prevent postoperative delirium and neurocognitive de-
cline, prompted by findings of the association between
low intraoperative EEG index values or burst-suppression
patterns and postoperative delirium [1–3]. The underlying
rationale is that reducing total anaesthetic dose and avoid-
ing EEG suppression might improve neurocognitive out-
comes. Prospective randomised clinical trials (RCTs)
comparing titration of anaesthesia to processed EEG index
ranges versus clinical signs have demonstrated reductions
in postoperative delirium [1, 4]. However, the merit of tar-
geting particular EEG index values or patterns, compared
to purely avoiding the suppression pattern, is not known.
In our previous observational work of EEG patterns
during maintenance and emergence from general an-
aesthesia, we have observed a variety of patterns in
the EEG prior to waking [5, 6]. Although there is not
a consensus among anaesthesiologists of what it
means to be awake, we have started to distinguish be-
tween emergence and recovery from general anaesthe-
sia. When we use the term ‘emergence from
anaesthesia’ we are referring to the transition from
surgical anaesthesia to a state with outward signs of
cortical function (typically coordinated motor re-
sponses). One example would be eye contact in re-
sponse to verbal or light tactile stimulation.
Anaesthesia recovery is the transition from the end of
emergence to normal pre-operative neurocognitive
function. Defining when the actual complete period of
anaesthesia has ended, and the subject has returned
to a pre-anaesthesia baseline is difficult because a pa-
tient may be safe to discharge from the recovery
room before all of the sedating effects of anaesthesia
have subsided. Therefore, the complete recovery tra-
jectory may go undocumented.
We have previously found that delirium (or incom-
plete neurocognitive recovery) in the recovery room
seems to occur less often when patients display stronger
alpha (7–17 Hz) oscillations in the frontal EEG during
the emergence phase of anaesthesia [5, 6]. However,
frontal EEG alpha power during maintenance of an-
aesthesia is negatively correlated with pre-operative
cognitive impairment [7] and with advancing age [8–10],
and this could explain the propensity for postopera-
tive delirium. Nevertheless, the extent to which the
EEG alpha oscillation is subject to intraoperative
pharmacological manipulation has, thus far, gone
largely unexplored.
Previous EEG-based protective strategies have focussed
on targeting proprietary dimensionless index values, the
meaning of which are not well understood. However, the
EEG alpha oscillation is a specific hallmark of gamma-
amino-butyric-acid (GABA)-ergic anaesthesia [11].
Marked loss of frontal EEG alpha activity can occur
in response to noxious stimulation [12, 13] and the
frequency and power of alpha oscillations are sensitive
to changes in effect-site concentrations of volatile
agents and opioids [8, 14]. We hypothesise that a
maximal EEG alpha oscillation during general anaes-
thesia may represent an ideal anaesthetic state of both
adequate anti-nociception and appropriate anaesthetic
depth, which would represent a novel, individualised,
anaesthetic strategy.
We also plan to investigate the efficacy of an alter-
native strategy; transition to propofol during the
emergence phase of anaesthesia on the EEG patterns
observed during emergence from anaesthesia, with
the aim of preventing abrupt transitions in brain
state. This intervention has been shown to reduce the
incidence of emergence delirium in young children
[15, 16] but has not been investigated adequately in
older populations. As well as looking at EEG features
and trajectories, we will evaluate the effect of these
interventions on relevant clinical outcomes, particu-
larly the incidence of delirium in the post-anaesthesia
care unit (PACU).
Aims
To ascertain whether the EEG patterns observed in an
elderly population are amenable to modulation by
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titration of commonly used anaesthetic agents during
the maintenance and emergence phases of anaesthesia.
We will assess the efficacy of (1) titration of anaesthesia
to maximise the observed frontal EEG alpha oscillation
and (2) the addition of propofol as the main hypnotic
during emergence in preventing PACU delirium.
Hypotheses
1. The frontal observed EEG alpha oscillation is
amenable to modulation by active titration of
desflurane and opioid intraoperatively
2. Maximisation of the EEG alpha oscillation during
the maintenance phase of anaesthesia promotes
more alpha activity during subsequent emergence
from anaesthesia
3. Supplementation with intravenously administered
propofol promotes alpha activity during the
emergence phase of anaesthesia
4. Alpha-dominant EEG emergence trajectories are
associated with a lower incidence and/or severity of
PACU delirium and possibly later adverse clinical
outcomes
Secondary objectives
1. To confirm or refute previously observed
associations between maintenance and emergence
EEG features and PACU delirium
2. To collect multichannel EEG recordings from a
subset of patients to investigate associations
between multichannel EEG markers and subsequent
PACU delirium
3. To collect additional detailed data for possible
confounding factors, such as physiological insults
(hypotension, blood loss, hypothermia, urinary
catheterisation), as risk factors for PACU delirium,
and create a statistical predictive model
4. To investigate the prognostic utility of delirium
scores and their subcomponents for subsequent
adverse clinical outcomes and devise a specific
PACU-delirium diagnostic tool
5. To detect abnormalities in speech-language function
in PACU using an informal tool
6. To investigate whether the interventions have any
effects on other early and late clinical outcomes
such as early postoperative pain, recovery from
surgery, serious adverse events and longer-term
cognitive function
Methods
Sample selection and recruitment
Potential participants will be identified by screening of
the operating theatre lists. In order to allow participants
adequate time to decide if they wish to take part in the
study we plan to approach patients in reasonable time
before their surgery. This will be in person if they are
admitted to the ward, or by a telephone call. The con-
sent process will then be completed in person.
Inclusion criteria
Adults aged 60 years or over with capacity to provide in-
formed consent who are undergoing elective
non-cardiac surgery, which does not involve the head or
neck, with planned volatile-based general anaesthesia of
expected duration of at least 2 h
Exclusion criteria
Chronic pain with opioid requirement or concurrent use
of enzyme inducers, e.g. carbamazepine, phenytoin, illicit
substance use or excessive alcohol intake, refusal by pa-
tient or case anaesthetist responsible for patient’s care.
Study design
This is a prospective RCT using a 2 × 2 factorial design
stratified by pre-operative cognitive score and surgery
type. The 2 × 2 design means that each patient has a
50% chance of being allocated to each intervention. This
will result in four randomisation groups, each with equal
numbers of participants, namely (A) maintenance and
emergence interventions, (B) maintenance intervention
only, (C) emergence intervention only and (D) neither
intervention (Fig. 1). Figure 2 illustrates the planned data
collection at each time point in the study.
Randomisation and blinding
Assignment of study participants to intervention groups
will be performed using block randomisation [17], strati-
fied by cognitive status (determined by pre-operative
Montreal Cognitive Assessment (MOCA) score), surgery
type (vascular, orthopaedic and general/other) and site.
Pre-operative cognitive impairment is widely recognised
as a risk factor for postoperative delirium and we have
previously found that delirium risk appears to be lower
for non-spinal orthopaedic procedures [6]. The re-
searcher collecting intraoperative EEG data will perform
the randomisation, shortly prior to commencement of
the anaesthesia episode. The case anaesthetists will not
be blinded to the interventions. Participants will be
blinded to their interventions. Members of the research
team responsible for recruitment, baseline data collec-
tion and clinical outcome data observers for the PACU
scores and follow-up data collection will be blinded to
randomisation groups and intraoperative events. For
final analysis of the primary EEG outcomes, the raw
EEGs will be de-identified so that the researcher con-
ducting the analysis cannot identify the individual
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participant or the group allocation. We do not anticipate
unblinding will be necessary.
Anaesthesia conduct: all participants
To minimise potential confounding factors, the follow-
ing recommendations will be made to the case anaesthe-
tist for all groups:
1. Intravenous induction of anaesthesia with propofol
and fentanyl (or equipotent dose of sufentanil).
Maintenance anaesthesia with desflurane 0.5–1.2
minimum alveolar concentration (MAC) (age-
adjusted). Desflurane has been chosen for
consistency of offset, given its low lipid insolubility
compared to sevoflurane and isoflurane
2. Fentanyl or sufentanil will be the only opioid
analgesics permitted for both groups
intraoperatively
3. Acceptable dose ranges of opioid and volatile
anaesthesia to be decided and confirmed between
the case anaesthetist and research team before
starting the case
4. Avoidance of midazolam, total intravenous
anaesthesia (TIVA), N2O, haloperidol, droperidol,
tramadol, ketamine or clonidine intraoperatively as
these may reasonably be expected to contribute to
or prevent delirium or affect EEG parameters
5. Ondansetron, dexamethasone, metoclopramide and
cyclizine are permitted intraoperatively, if deemed
necessary for prophylaxis of postoperative nausea
6. Paracetamol/local anaesthesia/regional anaesthesia/
non-steroidal anti-inflammatory drugs (NSAIDs)
may be used freely by the case anaesthetist
7. Clinicians will be asked to avoid the burst
suppression EEG pattern during maintenance phase
of anaesthesia in all groups
8. The case anaesthetist has ultimate responsibility for
the patient and will have discretion to overrule
suggestions by the research team
9. Stimulation during the emergence phase of
anaesthesia will be avoided as much as possible
10. Patient will be extubated on signs of return of
consciousness, e.g. following loud repeated
commands to open eyes/mouth
Fig. 1 Study conduct flow sheet illustrating factorial design and data collection points
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First randomisation: maintenance phase of anaesthesia
Participants will be randomised to intraoperative oscilla-
tory EEG alpha optimisation (Intervention 1) versus
standard care (with burst suppression alert).
Intervention 1 involves real-time acquisition of oscilla-
tory alpha power from the frontal EEG (recorded with
the standard EEG electrode strip from the Entropy Mod-
ule (GE Healthcare, Chicago, IL, USA) or the Bispectral
Index (BIS) (Medtronic, Minneapolis, MN, USA) or
other quantitative EEG monitor. An individual patient
value for the maximal oscillatory alpha power ‘Alpha
Max’ will be determined following induction of anaes-
thesia by variation of the end-tidal desflurane concentra-
tion prior to surgical incision. Effect-site concentrations
of volatile and opioid will be estimated in real time to
inform decisions around drug titration. During the intra-
operative phase, we will aim to maximise oscillatory
alpha EEG activity by individualised titration of desflur-
ane and opioid. If alpha activity suddenly drops, the case
anaesthetist will be advised to give a 0.5–1 mcg/kg bolus
of fentanyl. Target end-tidal desflurane concentration
will be adjusted according to real-time dose-response in-
formation. Typically, the concentration will be reduced
in response to sustained loss of alpha activity; however,
desflurane will not be reduced if quantitative EEG indi-
ces exceed a pre-defined threshold, to avoid awareness.
For example, the State Entropy (SE) from the GE En-
tropy Module will be maintained below 60. The Alpha
Max target will be adjusted intraoperatively if a new
maximum is reached at any stage. The titrations will occur
within prearranged limits agreed by the research team and
the case anaesthetist and taking into account the clinical
context, for example the degree of surgical stimulation.
For those patients randomised to standard care, anaes-
thesia will be conducted as per usual care by the anaes-
thetist, with quantitative processed EEG index values
(e.g. State Entropy) and EEG waveforms visible as per
the standardised protocol).
Second randomisation: emergence phase of anaesthesia
Participants will be randomised to conversion to a pro-
pofol infusion for emergence from anaesthesia (Interven-
tion 2) versus control (standard emergence from volatile
anaesthesia).
This intervention will be achieved by infusion of pro-
pofol 400 mg/h and simultaneous reduction of inspired
desflurane concentration during the final 10–20min of
surgery. Boluses of propofol may be given as required to
keep acceptable quantitative EEG index values until sur-
gery is complete. Total doses of propofol administered
are likely to be in the range 1–3 mg/kg, which is com-
parable to the effective dose in children.
Primary outcomes
Intervention 1
 Oscillatory EEG alpha power during the
maintenance phase of anaesthesia
Fig. 2 SPIRIT diagram demonstrating planned data collection
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Intervention 2
 Oscillatory EEG alpha power during the emergence
phase of anaesthesia
Our primary trial outcomes are EEG outcomes (rather
than clinical outcomes) because it is important firstly to
determine whether the interventions, which are novel,
do indeed have the anticipated effects on the intraopera-
tive EEG parameters. Oscillatory alpha [12] is chosen as
the outcome of neurophysiological interest because the
total power in the frequency band is subject to general
slowing of the EEG signal, and so the frequency of the
alpha oscillation can drift outside the traditionally de-
fined alpha frequency band.
Secondary outcomes
Intraoperative outcomes: EEG
 Maintenance phase
○ Proportion of time with EEG alpha power > 70%
of Alpha Max (the maximal EEG alpha power)
○ Burst suppression duration
○ Quantitative EEG indices
 Emergence phase
○ EEG emergence trajectories
○ Sequence and dynamics of slow wave (alpha and
delta) activity and non-slow wave activity
We plan to evaluate the effectiveness of the intraoper-
ative EEG alpha power-maximisation intervention by
calculating the proportion of the maintenance phase
during which the alpha oscillation is close to the max-
imum seen for that patient. This applies to the interven-
tion group only since in the control group the maximal
EEG alpha power will not be targeted. In addition to the
primary outcome of oscillatory EEG alpha power, we will
report on burst suppression and quantitative EEG indi-
ces. The EEG emergence trajectory patterns, in particu-
lar the presence or absence of abrupt state transitions,
will also be categorised. A subset of patients will
undergo multichannel EEG recording in addition to
frontal EEG monitoring using locally available equip-
ment, for later exploratory analyses.
Intraoperative outcomes: other
 Total opioid and desflurane administered
intraoperatively
 Total muscle relaxant dose
 Hypotension (duration mean arterial pressure < 60
mmHg)
It is likely that the EEG alpha power-maximisation
strategy will result in different patterns of administra-
tion of opioids and volatiles from the control group,
which we will report. This could also result in differing
muscle relaxant requirements and differences in intra-
operative haemodynamic stability. In addition, we will
collect feedback from the clinicians as to the accept-
ability of the protocol and the extent of any deviation
from their usual care.
Immediate clinical outcomes: PACU
 Interval from extubation to fit-for-discharge status
(achievement of Post Anaesthesia Recovery Score
(PARS) score of 10/12 or more) from PACU
 PACU delirium
○ 3D-CAM (and 3D-CAM-Severity)
○ 3D-CAM features
○ Nursing Delirium Screening Scale (NuDESC)
○ Richmond Agitation-Sedation Score (RASS)
○ Confusion Assessment Method for the Intensive
Care Unit (CAM-ICU)
○ Speech-language screen
○ Requirement for pharmacological and non-
pharmacological management of delirium
 PACU pain, nausea and vomiting
○ Numerical rating score
○ Opioid requirement
○ Naloxone requirement
The ideal way to quantify neurocognitive recovery
from anaesthesia is unclear so we intend to investigate a
number of potential markers of both speed and quality
of recovery. Extubation and fitness for discharge from
PACU are easily recognised and readily recordable time
points. A number of tools have been used to diagnose
delirium in PACU, with variable performance [18, 19]. A
Diagnostic and Statistical Manual of Mental Disorders,
fifth edition (DSM-V) assessment by a trained physician
or psychologist is usually considered the ‘gold standard’
for diagnosis of delirium; however, this is neither prac-
tical nor necessarily appropriate in the immediate
post-surgical period; however, there is no single recom-
mended PACU-delirium assessment tool [20]. The
3D-CAM [21] is a well-validated diagnostic instrument
which we have found to be feasible in PACU in a small
pilot study and this will be used as our main
PACU-delirium outcome measure. In addition, we will
perform the CAM-ICU, the NuDESC and a speech lan-
guage screen to further cover the key neurocognitive do-
mains. Our observations indicate that some patients
experience language and/or cognitive communication
deficits in PACU. Accordingly the inclusion of an infor-
mal speech-language screen may yield valuable informa-
tion not typically obtained from delirium assessment
tools. Tasks unique to this screen include category flu-
ency, naming to definition and narrative production.
Subsequent analysis of the later clinical outcomes will
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help to determine which features or scores are most im-
portant and of greatest prognostic value. Use of re-
straints or requirement of pharmacological treatment for
PACU delirium will also be recorded. Since the EEG
alpha power-maximisation strategy is hoped to maintain
an optimal anti-nociceptive state intraoperatively, we will
also examine whether there is any reduction in pain in
PACU, using the numerical rating score and opioid re-
quirements as the markers of this outcome. We will also
record any requirement for naloxone reversal of opioid
effect as a marker of excessive opioid administration.
Further clinical outcomes
 Quality of recovery (day 1 and day 30) – QOR-15
 Modified Brice Interview (day 1 and day 30)
 Hospital length of stay and discharge destination
 Days alive at home 30 days after surgery
 Serious adverse events (falls, unplanned high-
dependency or intensive care unit admission, stroke
or myocardial infarct, surgical site infection, hospital
readmission and death) up to 12 months
 Cognitive status at 12 months (telephone Montreal
Cognitive Assessment (tMOCA))
The QOR-15 is a validated score reflecting overall qual-
ity of recovery from anaesthesia and surgery [22, 23]. The
Modified Brice Interview [24, 25] is used to check for
awareness with recall. Days alive at home (DAAH) has
been chosen as a validated patient-centred outcome meas-
ure that is readily quantifiable and reflects duration of
hospitalisation, discharge destination and mortality [26].
Serious adverse events will also be recorded, from patient
report and note review out to 12months postoperatively
to look at longer-term recovery and later serious compli-
cations. We will also conduct a tMOCA at 12months as a
final cognitive evaluation [27].
Supplementary routine data collection
Baseline data
Use of hearing and visual aids will be recorded and these
made available to the patient for the PACU assessments.
We plan to collect standard demographic data including
American Society of Anesthesiologists (ASA) score and
planned surgery. Cognitive impairment is a known risk
factor for the development of postoperative delirium
[20] and will be used to stratify randomisation. The
MOCA will be used to quantify cognitive status
pre-operatively. In addition, some items from the
3D-CAM will be assessed at baseline to determine
whether later errors in the 3D-CAM in PACU reflect a
change from baseline performance. Pre-operative pain
and anxiety will be recorded using the relevant questions
from the QOR-15 questionnaire. The National Surgical
Quality Improvement Programme (NSQIP) surgical risk
calculator surgical complications risk [28] will also be
calculated for each patient to potentially allow for risk
adjustment in statistical analyses.
Intraoperative data
Intraoperative physiological data will be extracted from
the operating room monitors using a custom-designed
computer programme. Collected data will include heart
rate, blood pressure, oxygen saturation, temperature,
end-tidal carbon dioxide and volatile anaesthetic con-
centrations and the frontal EEG waveform and quantita-
tive EEG indices. Additional EEG information will be
obtained for a subgroup of consenting participants to in-
vestigate multichannel EEG features.
Effect-site concentrations of fentanyl and desflurane
will be calculated and further EEG processing per-
formed in real time. The oscillatory EEG alpha mag-
nitude and dose-response relationships will be
displayed to verify the oscillatory EEG alpha optimisa-
tion intervention.
The anaesthetic record will be photocopied so as to
have a record of all administered medications. Pertinent
event data, such as regional anaesthesia, estimated blood
loss, total intravenous fluid volume administered and
urinary catheterisation will be recorded routinely.
Data management
Baseline data and clinical outcome data will be entered
and managed using REDCap electronic data capture tools
hosted at the University of Auckland, New Zealand. RED-
Cap (Research Electronic Data Capture) is a secure,
web-based application designed to support data capture
for research studies, providing (1) an intuitive interface for
validated data entry; (2) audit trails for tracking data ma-
nipulation and export procedures; (3) automated export
procedures for seamless data downloads to common stat-
istical packages and (4) procedures for importing data
from external sources [29]. Intraoperative vital sign and
EEG time-series data will be saved in real time to a com-
puter used solely for data collection. At the end of a par-
ticipant’s anaesthesia, the files will be transferred and
stored on a secure server.
Data safety monitoring
Risks to participants are expected to be minimal; the in-
terventions being trialled are within the realms of
current anaesthetic practice and the case anaesthetist
will have the autonomy to digress from protocol in clin-
ical interests of patients, e.g. if the doses suggested seem
outside acceptable clinical practice. The primary risks
that have been identified are light anaesthesia (with in-
creased but still very low risk of awareness with recall)
or deep anaesthesia and inadequate or excessive intraop-
erative analgesia. These risks will be measured and
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mitigated by the use of agreed dosage upper and lower
limits, quantitative EEG monitoring, and interim analysis
of PACU pain data. No formal interim analyses are
planned; however, we will be taking informal feedback
from clinicians throughout the trial and will review any
unanticipated issues which arise.
A data safety monitoring committee will consist of
two independent anaesthetists with research expertise.
Any adverse events will be recorded and then cate-
gorised as to severity and the likelihood of the event
having occurred as a result of the study. Adverse events
will be reviewed regularly by the committee and the
committee will make recommendations to the research
team. Should any serious adverse events occur which are
deemed due to the study itself, these will be communi-
cated immediately to the committee to consider whether
the trial should be suspended.
Statistical analysis and power calculations
We intend to recruit 600 participants. The 2 × 2 factorial
design will result in 300 patients assigned to the main-
tenance phase intervention and 300 to the emergence
phase intervention (see Fig. 1). This will ensure that the
study will be well-powered for the primary EEG out-
comes and sufficiently powered to detect moderate-large
effects in the secondary clinical outcomes. Our primary
analyses will be intention to treat; however, per-protocol
analyses will also be reported. For the primary outcome
for the maintenance phase Alpha Max intervention,
alpha power in groups A and B (Fig. 1) pooled together
will be compared to groups C and D. For the primary
outcome for the emergence phase intervention, groups
A and C (Fig. 1) will be compared to groups B and D
pooled. The crude difference will be reported as the pri-
mary outcome; however, an adjusted estimate will also
be provided for the emergence outcome. This will in-
clude an interaction term for the maintenance phase
intervention, since one might reasonably expect alpha
power in the emergence phase to correlate with alpha
power in the maintenance phase.
EEG analysis will be performed using customised
script in MATLAB. Our previous summary data suggest
that a mean oscillatory alpha power of 4.75 dB with
standard deviation of 2.1 dB might be expected in a gen-
eral surgical population. Therefore, an estimated 230 pa-
tients are required to have 95% power to detect an
increase in oscillatory alpha of at least 1 dB (equivalent
to ~ 20% relative increase in alpha power in response to
the fentanyl) in the intervention group compared with
the control group (two-tailed alpha 0.05, beta 0.05); thus,
with a planned total of 300 patients per group we are
comfortably overpowered for this outcome.
PACU delirium is our clinical outcome of primary
interest, as a marker of neurocognitive recovery from
anaesthesia. In our previous observational study, the in-
cidence of CAM-ICU-diagnosed PACU delirium was
16% in those over 60 years and in a subsequent depart-
mental audit, the incidence of PACU delirium diagnosed
using the NuDESC tool was around 20% in those aged
65 years and over. Given that the study inclusion criteria
requires > 2 h of anaesthesia, study participants will
likely in general be having more extensive surgery and
longer anaesthesia than those in the previous study and
audit; therefore, we conservatively estimate a 20% inci-
dence of PACU delirium in the control groups. From
our observational work, the presence of EEG alpha has
an odds ratio of approximately 0.5 for PACU delirium
(unpublished data). Five hundred and thirty-two patients
would be required to demonstrate a decrease in PACU
delirium from 20 to 10% with 90% power (two-tailed
alpha 0.05, beta 0.1, χ2 test). Thus, the study is powered
to demonstrate strategies which have a large impact in
preventing the development of delirium.
Almost certainly this study will also be sufficiently
powered for minimum clinically important effects in
some of the other secondary outcomes including delir-
ium subcomponent features, days alive and out of hos-
pital, and quality of recovery. We plan to recruit 600
patients to allow for loss to follow-up and a lower inci-
dence of delirium than expected.
Continuous outcomes will be assessed using t tests
and analysis of variance (ANOVA), ordinal with rank
sum, and categorical outcomes will be assessed using the
χ2 test, with significance set at p < 0.05. Non-linear
mixed-effect modelling will be incorporated where ap-
propriate to account for propensities such as: patient
maximum alpha power, within-patient fentanyl and des-
flurane dose-response relationships and characteristics
of the anaesthetic technique. Interactions between the
two interventions are possible and will be examined. We
also plan to carry out multivariate logistic regression to
determine the major risk factors for the development of
the features of PACU delirium, and receiver operator
curve analysis to determine which elements of the early
delirium screening tools are most closely associated with
adverse clinical outcomes. We anticipate performing fur-
ther exploratory analyses in addition to those explicitly
defined pre-operatively.
Ethical considerations
Older patients undergoing surgery constitute a poten-
tially vulnerable population. Participants will be
approached and consented by experienced research staff.
We plan to only include participants who have given in-
formed consent for surgery (or are expected to give their
own consent for surgery) and, thus, would also be ex-
pected to be competent to consent to research. In
addition, the research team will have discretionary ability
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to exclude participants should they feel that the patient
is unable to sufficiently understand and consent to the
study. However, it may be that some patients achieve
scores much lower than is expected or normal for their
age. It is important that this group is included in the
study as they constitute a patient group that will poten-
tially benefit most from the interventions.
Participants will be encouraged to discuss the study
with any support people they wish and research staff will
explain the study to support persons to aid
decision-making. In order to assure that our study par-
ticipants are capable of understanding the information
provided in the informed consent, a further single ques-
tion screen will be used to detect inadequate health liter-
acy. ‘Are you confident filling out medical forms by
yourself?’ has been used previously to detect poor health
literacy [30]. If the answer to this question is ‘no’ or the
pre-operative MOCA score is very low (less than 15/30)
and it appears that the patient is unable to fully under-
stand the implications of taking part in the study, they
will be excluded from the study and the clinical team
will be informed. We will check during the consent
process the participant’s wishes about information dis-
closure should we detect early cognitive impairment and
these wishes will be followed. The usual clinical standard
of preservation of confidentiality will be preserved; data
will not be published or shared in any such way that
would reasonably be expected to identify individuals.
Discussion
As far as we are aware, this will be the first RCT
whereby anaesthesia is titrated to the observed frontal
EEG alpha oscillation, rather than quantitative EEG
index values. Furthermore, we hope to establish the de-
gree of association between intraoperative alpha activity
and PACU delirium, which is unclear at present.
Features of anaesthesia and delirium overlap consider-
ably and it is difficult to define when anaesthesia emer-
gence ends. Current nomenclature can be quite
confusing with terms such as emergence agitation,
hypoactive, hyperactive, PACU delirium and postopera-
tive delirium employed for somewhat similar states,
which also fluctuate with time. The syndrome we are
evaluating may in fact better be considered a delayed or
incomplete neurocognitive recovery from anaesthesia.
This clinical relevance of this syndrome is unclear and it
is relatively sparsely represented in the literature; how-
ever, the small body of existing evidence suggests that
PACU delirium is associated with multiple adverse clin-
ical outcomes [31]. With this study we hope to establish
whether this is simply a result of existing patient and
surgical factors or if optimisation of anaesthesia might
be protective.
The optimal assessment tool to measure delirium in
the PACU environment is unclear. We have elected to
use the 3D-CAM score as our main clinical outcome
measure but we will also take the opportunity to evalu-
ate and compare some other candidate scores. A second-
ary objective of the study will be to evaluate which
features of delirium are most closely associated with
later adverse outcomes. A recent consensus guideline
[20] has recommended routine screening of patients for
delirium prior to discharge from the recovery room;
however, it does not specify a particular tool. Ideally the
assessment tool should identify patients at risk of subse-
quent deterioration and adverse clinical outcomes. We
plan to evaluate the performance of 3D-CAM in this re-
gard, and to possibly create a tool specifically for an im-
mediate post-anaesthesia care episode.
This study has been approved by the New Zealand
Health and Disability Ethics Committee ref. 17/NTA/56
and has local intstitution approval at Waikato Hospital.
Ethics/IRB approval and local institutional approval will
be obtained prior to commencement of the study at
other sites. Recruitment began in February 2018 at our
primary site with plans for at least two international col-
laborating sites to join. As of October 2018, we have re-
cruited 60 patients. Data collection is expected take 3–4
years. Dissemination plans include presentations at sci-
entific conferences and publication in peer-reviewed
journals.
Study sites
The study will be carried out across three sites with pos-
sible later inclusion of additional sites:
 Waikato DHB Department of Anaesthesia, Waikato,
New Zealand
 Technical University of Munich, Munich, Germany
 Columbia University Medical Center, Ithaca, NY, USA
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